PBM Cross-Book Pricing Commitments: Price Concessions Without a Refund Check

PBM generic effective rate cross book offsets can use higher Part D pharmacy payments to reduce the PBM’s commercial reconciliation obligation. The pharmacy benefit manager counts the Part D payments toward a combined pharmacy pricing commitment, lowering its commercial obligation without sending the plan sponsor a refund check. If you work with pharmacy contracts, pricing or year-end true-ups, you may recognize the disconnect: a payment counted toward the commercial bargain disappears from the account of what Medicare drugs actually cost. The workbook can show a concession that the prescription claim never explains.

How Caremark’s Cross-Book Offset Worked

Caremark’s higher Part D payments to Walgreens and Rite Aid, measured against the overall pricing commitment, reduced its commercial reconciliation obligation. The court treated that reduction as an economic concession that Part D reporting had to reflect.

The accounting connected the books. Part D pharmacy payments contributed to satisfying the combined pricing commitment. That contribution reduced the amount Caremark otherwise owed on the commercial side. Looking only for cash returned to the Part D sponsor would miss the benefit Caremark obtained through the reduced commercial obligation.

No refund check. Still a saving.

An Aetna Medicare actuary brought the whistleblower case after comparative prices raised questions about the pricing commitments and Part D reporting. In its June 25, 2025 findings, the court found Caremark’s reporting for the Walgreens and Rite Aid transactions false.

The court assessed $95 million in damages before tripling them and adding penalties. On August 19, 2025, it entered a $289,873,500 judgment against Caremark. The penalties attached to 513 false plan-level direct and indirect remuneration reports.

How a Generic Effective Rate Commitment Works

A generic effective rate commitment measures generic pricing across the purchases covered by an agreement. The contract defines the drugs, claims and period included in that calculation. A true-up reconciles the actual result with the promised rate and determines the adjustment owed.

A pharmacy payment, the pharmacy benefit manager’s charge to a plan sponsor and a payment to settle the pricing commitment belong to different parts of the transaction. Caremark’s overall generic effective rate commitments combined commercial and Medicare Part D purchases at Walgreens and Rite Aid.

Average wholesale price supplies a contractual reimbursement benchmark, while the pharmacy’s purchasing invoice shows what it paid for the medicine. That is why an apparently attractive generic discount needs its denominator. Which purchases count? Which claims were excluded? Which pharmacy payments entered the calculation? A rate applied to one population and tested against another can tell the sponsor very little about whether its bargain was met.

The Contract Decides What Can Offset What

Contract definitions determine whether performance in one category can cover a shortfall in another. The reconciliation formula gives those definitions their financial effect.

Delaware’s 2015 amendment with Express Scripts, for example, prohibited offsetting one rebate category’s shortfall with another’s surplus. It separately required reimbursement of a shortfall under its annual specialty average-wholesale-price commitment. An analyst reviewing performance needed the category results and the annual calculation to see whether Express Scripts had met them.

The same work connects the network agreement, pharmacy remittances, sponsor invoices and year-end reconciliation. A claims file shows the transactions processed. The final remittance shows adjustments to what the pharmacy received. The sponsor invoice shows what the plan paid. The true-up shows how the contract used those amounts to settle the pricing commitment.

Spread pricing describes the difference between the sponsor’s charge and the pharmacy’s reimbursement. A later reconciliation adjustment can change that result. Under the pass-through model in Ohio’s July 2020 baseline Medicaid contract, pharmacy pricing and a separate administrative fee were distinct. The contract and the final reconciliation show how the pharmacy benefit manager was paid from the plan’s health care spending.

What Does 100 Percent Pass-Through Cover?

A pass-through promise covers the receipts the contract defines. Minnesota’s Caremark agreement, effective January 2021, promised all defined rebates received by the pharmacy benefit manager or an affiliate. The agreement’s rebate definition included specified formulary, market-share, price-protection, administrative and program payments. It excluded described mail and specialty purchasing discounts and specified specialty service revenue.

The percentage can be complete while the defined category leaves money elsewhere. An affiliate receipt can sit outside the rebate category and never enter the sponsor’s reconciliation.

What the Point-of-Sale Audit Left Out

The point-of-sale audit in the Caremark case excluded direct and indirect remuneration, the concessions that affect Part D drug costs. It examined a different layer from the later concession accounting at the center of the case.

The court identified reconciliation workbooks, an internal pricing slideshow, sponsor-reporting attestations and testimony from the contract, pharmacy, sponsor and finance sides. Its findings also described legal review based on representations made without the contracts and workbooks. The Centers for Medicare & Medicaid Services had not been told how the offsets worked.

We find the omission striking. The favorable review left out the accounting that explained the saving.

For an insider, these records have recognizable owners. Contract staff know the pricing commitment’s scope and exclusions. Finance can explain the reconciliation and the commercial obligation it reduced. Pharmacy remittances show the payments and later adjustments. Sponsor-reporting teams hold the extracts and attestations through which those transactions become a report to Medicare.

Claim reversals, rebills and year-end adjustments can change the result after the initial payment. We follow those changes with you to connect the commercial saving to the report Medicare received.

The Saving Still Belongs in the Part D Account

A sponsor’s right to receive a payment under its PBM contract and its duty to report drug costs to Medicare are separate questions. Part D’s actually-paid rules account for concessions that reduce drug costs, including remuneration an intermediary retains.

The Centers for Medicare & Medicaid Services’ Prescription Drug Event data guide explains that prescription drug event data are summary extracts using fields the agency defines. The underlying pharmacy claim, the generated event data and the annual direct and indirect remuneration report each answer a different accounting question. A review of event data alone leaves separate rebate and final reconciliation information out of view.

Delegated reporting adds another handoff. Contractors generating claims data certify to the sponsor, while the sponsor’s authorized officers or delegate certify the payment data connected to federal reimbursement. The reporting attestations matter because they connect the business’s calculations to the government’s payment.

The Point-of-Sale Change Still Leaves a Final Reconciliation

The Part D pharmacy-concession change moved concessions into the initial negotiated price for 2024. The agency’s rule issued in 2022 changed that price to the pharmacy’s lowest possible reimbursement, including pharmacy concessions.

The reporting instructions for service year 2024 still paired the estimated point-of-sale concession with the difference between negotiated price and final pharmacy reimbursement. Together, those entries accounted for actual remuneration.

Further changes have their own timing. The PBM provisions enacted in February 2026 set new Part D sponsor-PBM agreement and remuneration requirements for plan years beginning in 2028. They include transparent pricing commitment definitions and exclusions, affiliate information and sponsor-selected audits.

Other PBM Cases Follow Different Accounting Paths

Elixir’s rebate case followed a classification inside annual Part D reporting. The government alleged that Elixir Insurance Company excluded retained manufacturer rebates by treating them as service fees. The civil settlement announced in July 2024 addressed those allegations.

The whistleblower’s complaint challenged whether EPS, the company retaining the rebates, performed any manufacturer service in exchange:

The government’s account also alleged retention without manufacturers’ knowledge. The service agreement, manufacturer remittance, retained amount and sponsor classification supplied the accounting trail. Here the question was what a receipt represented and how it entered the report.

Ohio’s case against Centene followed another path through Envolve and Buckeye. The state alleged that Envolve invoiced Buckeye for more than Caremark had invoiced Envolve, omitted a retail credit and classified an added amount as a dispensing fee even though it had not gone to the dispensing pharmacy. Ohio and Centene settled the state case in June 2021.

Those allegations put the supplier invoice, affiliate invoice, credit and reported pharmacy expense side by side. Caremark’s cross-book judgment instead turned on how payments counted toward a combined pricing commitment. Both make the records after the prescription claim worth understanding: what value moved, who received the benefit and what the payer was told.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Firsthand knowledge of the reconciliation or reporting process gives us the connection between the business’s calculation and the amount reported to the government.

When You Know the Reconciliation

If you know how a pharmacy pricing commitment became a commercial offset or disappeared from a Part D report, speak to our whistleblower experts about the calculation. We work through what you observed and questions about the records, then build your healthcare fraud case around the contracts, the accounting and the reporting decisions. We bring in PBM fraud whistleblower lawyers who understand pricing reconciliation and stay with you throughout the case.